Chesapeake Asset Management’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.81M | Sell |
15,053
-1,113
| -7% | -$128K | 1.44% | 14 |
|
|
2025
Q4 | $1.7M | Sell |
16,166
-984
| -6% | -$92.4K | 1.41% | 13 |
|
|
2025
Q3 | $1.44M | Sell |
17,150
-8,044
| -32% | -$663K | 1.27% | 18 |
|
|
2025
Q2 | $1.99M | Sell |
25,194
-316
| -1% | -$25.1K | 1.79% | 12 |
|
|
2025
Q1 | $2.29M | Sell |
25,510
-3,432
| -12% | -$320K | 2.15% | 10 |
|
|
2024
Q4 | $2.88M | Buy |
28,942
+40
| +0.1% | +$4.12K | 2.68% | 9 |
|
|
2024
Q3 | $3.28M | Sell |
28,902
-2,960
| -9% | -$352K | 2.85% | 7 |
|
|
2024
Q2 | $3.94M | Sell |
31,862
-210
| -0.7% | -$27.1K | 3.77% | 4 |
|
|
2024
Q1 | $4.23M | Sell |
32,072
-6,919
| -18% | -$853K | 4.18% | 4 |
|
|
2023
Q4 | $4.25M | Buy |
38,991
+259
| +0.7% | +$26.9K | 3.79% | 4 |
|
|
2023
Q3 | $3.99M | Sell |
38,732
-3,148
| -8% | -$339K | 3.87% | 4 |
|
|
2023
Q2 | $4.83M | Sell |
41,880
-2,794
| -6% | -$317K | 4.36% | 3 |
|
|
2023
Q1 | $4.75M | Buy |
+44,674
| New | +$4.82M | 4.35% | 3 |
|
|
2019
Q4 | $3.15M | Hold |
36,270
| – | – | 5.33% | 5 |
|
|
2019
Q3 | $2.91M | Sell |
36,270
-2,781
| -7% | -$223K | 5.48% | 5 |
|
|
2019
Q2 | $3.12M | Sell |
39,051
-157
| -0.4% | -$12K | 5.15% | 5 |
|
|
2019
Q1 | $3.11M | Sell |
39,208
-12,649
| -24% | -$946K | 5.29% | 5 |
|
|
2018
Q4 | $3.78M | Sell |
51,857
-1,347
| -3% | -$95.1K | 6.97% | 3 |
|
|
2018
Q3 | $3.6M | Sell |
53,204
-7,687
| -13% | -$490K | 4.14% | 5 |
|
|
2018
Q2 | $3.53M | Sell |
60,891
-10,972
| -15% | -$619K | 4.11% | 5 |
|
|
2018
Q1 | $3.73M | Sell |
71,863
-1,648
| -2% | -$89K | 4% | 5 |
|
|
2017
Q4 | $3.95M | Sell |
73,511
-3,825
| -5% | -$212K | 3.81% | 5 |
|
|
2017
Q3 | $4.72M | Sell |
77,336
-367
| -0.5% | -$22.3K | 4.26% | 6 |
|
|
2017
Q2 | $4.75M | Sell |
77,703
-792
| -1% | -$48.2K | 4.52% | 4 |
|
|
2017
Q1 | $4.76M | Sell |
78,495
-446
| -0.6% | -$27.1K | 3.92% | 6 |
|
|
2016
Q4 | $4.43M | Sell |
78,941
-104
| -0.1% | -$6.09K | 3.84% | 6 |
|
|
2016
Q3 | $4.71M | Hold |
79,045
| – | – | 4.26% | 5 |
|
|
2016
Q2 | $4.34M | Sell |
79,045
-8,384
| -10% | -$446K | 3.53% | 7 |
|
|
2016
Q1 | $4.41M | Hold |
87,429
| – | – | 3.66% | 8 |
|
|
2015
Q4 | $4.41M | Sell |
87,429
-406
| -0.5% | -$20.5K | 3.39% | 8 |
|
|
2015
Q3 | $4.14M | Hold |
87,835
| – | – | 3.52% | 8 |
|
|
2015
Q2 | $4.77M | Hold |
87,835
| – | – | 3.5% | 8 |
|
|
2015
Q1 | $4.82M | Hold |
87,835
| – | – | 3.55% | 8 |
|
|
2014
Q4 | $4.76M | Sell |
87,835
-576
| -0.7% | -$32.1K | 2.98% | 5 |
|
|
2014
Q3 | $5M | Hold |
88,411
| – | – | 3.05% | 3 |
|
|
2014
Q2 | $4.88M | Hold |
88,411
| – | – | 3.03% | 4 |
|
|
2014
Q1 | $4.79M | Buy |
88,411
+14,934
| +20% | +$773K | 3.24% | 3 |
|
|
2013
Q4 | $3.51M | Hold |
73,477
| – | – | 2.08% | 20 |
|
|
2013
Q3 | $3.34M | Sell |
73,477
-1,625
| -2% | -$74.2K | 2.24% | 15 |
|
|
2013
Q2 | $3.33M | Buy |
+75,102
| New | +$3.35M | 2.4% | 13 |
|
Other funds holding MRK
VCM
VPM
Chesapeake Asset Management's MRK Position: Q1 2026 in Review
Chesapeake Asset Management reduced its Merck (MRK) stake by 6.9% in Q1 2026, selling an estimated $128K and leaving 15,053 shares worth $1.81M. The position accounts for 1.44% of the portfolio, ranked #14.
Chesapeake Asset Management first reported a position in MRK in Q2 2013 and has held it in 40 quarters since. The position peaked at $5M in Q3 2014. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Chesapeake Asset Management held 15,053 shares of Merck worth $1.81M as of Q1 2026.
- Chesapeake Asset Management sold 1,113 Merck shares in Q1 2026, an estimated $128K.
- Merck made up 1.44% of Chesapeake Asset Management's portfolio in Q1 2026, its #14 holding.
- Chesapeake Asset Management first reported a position in Merck in Q2 2013 and has held it in 40 quarters since.
- Chesapeake Asset Management's Merck position peaked at $5M in Q3 2014.
- 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Chesapeake Asset Management's 13F filing for Q1 2026, filed 12 May 2026.